[go: up one dir, main page]

RU2002118308A - Methods for producing polymorphic modifications of clarithromycin - Google Patents

Methods for producing polymorphic modifications of clarithromycin

Info

Publication number
RU2002118308A
RU2002118308A RU2002118308/15A RU2002118308A RU2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308/15 A RU2002118308/15 A RU 2002118308/15A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A
Authority
RU
Russia
Prior art keywords
clarithromycin
water
suspending
converting
suspended
Prior art date
Application number
RU2002118308/15A
Other languages
Russian (ru)
Inventor
Игорь ЛИФШИЦ (IL)
Игорь ЛИФШИЦ
Иль АВРУТОВ (IL)
Илья АВРУТОВ
Эди ШВАРЦ (IL)
Эди ШВАРЦ
Басем МАСАРВА (IL)
Басем МАСАРВА
Original Assignee
Тева Фамэситикл Индастрис Лтд. (Il)
Тева Фамэситикл Индастрис Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2002118308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фамэситикл Индастрис Лтд. (Il), Тева Фамэситикл Индастрис Лтд. filed Critical Тева Фамэситикл Индастрис Лтд. (Il)
Publication of RU2002118308A publication Critical patent/RU2002118308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to processes for converting clarithromycin Form I to clarithromycin Form II, which include slurrying clarithromycin the Form I in water. The present invention also relates to processes for the preparation of clarithromycin Form II by converting erythromycin A to clarithromycin and thereafter converting clarithromycin Form I to clarithromycin Form II by slurrying.

Claims (15)

1. Способ превращения полиморфной Формы I кларитромицина в полиморфную Форму II, включающий суспендирование твердого вещества, содержащего кларитромицин Формы I, в воде.1. A method for converting a polymorphic Form I clarithromycin into a polymorphic Form II, comprising suspending a solid containing clarithromycin Form I in water. 2. Способ превращения Формы I кларитромицина в Форму II, включающий суспендирование Формы I кларитромицина в воде.2. A method for converting Form I clarithromycin to Form II, comprising suspending Form I clarithromycin in water. 3. Способ по п.2, отличающийся тем, что Форму I кларитромицина суспендируют в 2-25 мл воды на один грамм Формы I кларитромицина.3. The method according to claim 2, characterized in that Form I clarithromycin is suspended in 2-25 ml of water per gram of Form I clarithromycin. 4. Способ по п.2, отличающийся тем, что Форму I кларитромицина суспендируют в 3-10 мл воды на один грамм Формы I кларитромицина.4. The method according to claim 2, characterized in that Form I clarithromycin is suspended in 3-10 ml of water per gram of Form I clarithromycin. 5. Способ по п.2, отличающийся тем, что суспендирование проводят при комнатной температуре.5. The method according to claim 2, characterized in that the suspension is carried out at room temperature. 6. Способ по п.2, дополнительно включающий сушку Формы II кларитромицина, что является следствием суспендирования Формы I в воде.6. The method according to claim 2, further comprising drying the clarithromycin Form II, which is a consequence of the suspension of Form I in water. 7. Способ по п.6, отличающийся тем, что сушку проводят в вакууме.7. The method according to claim 6, characterized in that the drying is carried out in vacuum. 8. Способ получения Формы II кларитромицина, включающий превращение эритромицина А в кларитромицин Формы I и суспендирование Формы I кларитромицина в воде с образованием Формы II кларитромицина.8. A method of preparing Form II clarithromycin, comprising converting erythromycin A to clarithromycin Form I and suspending Form I clarithromycin in water to form Form II clarithromycin. 9. Способ по п.8, отличающийся тем, что кларитромицин Формы I суспендируют в 2-25 мл воды на один грамм Формы I кларитромицина.9. The method according to claim 8, characterized in that the clarithromycin Form I is suspended in 2-25 ml of water per gram of Form I clarithromycin. 10. Способ по п.8, отличающийся тем, что Форму I кларитромицина суспендируют в 3-10 мл воды на один грамм Формы I кларитромицина.10. The method according to claim 8, characterized in that Form I clarithromycin is suspended in 3-10 ml of water per gram of Form I clarithromycin. 11. Способ по п.8, отличающийся тем, что суспендирование проводят при комнатной температуре.11. The method according to claim 8, characterized in that the suspension is carried out at room temperature. 12. Способ по п.8, дополнительно включающий сушку Формы II кларитромицина, что является следствием суспендирования Формы I в воде.12. The method of claim 8, further comprising drying the clarithromycin Form II, which is a consequence of the suspension of Form I in water. 13. Способ по п.12, отличающийся тем, что сушку проводят в вакууме.13. The method according to p. 12, characterized in that the drying is carried out in vacuum. 14. Форма II кларитромицина, образованная суспендированием Формы I кларитромицина в воде.14. Form II clarithromycin formed by suspending Form I clarithromycin in water. 15. Фармацевтическая композиция, включающая терапевтически эффективное количество Формы II кларитромицина, образованной суспендированием Формы I кларитромицина в воде, и, по крайней мере, один фармацевтически приемлемый носитель.15. A pharmaceutical composition comprising a therapeutically effective amount of Form II clarithromycin formed by suspending Form I clarithromycin in water, and at least one pharmaceutically acceptable carrier.
RU2002118308/15A 2000-01-11 2000-12-15 Methods for producing polymorphic modifications of clarithromycin RU2002118308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
US60/175477 2000-01-11

Publications (1)

Publication Number Publication Date
RU2002118308A true RU2002118308A (en) 2004-02-20

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002118308/15A RU2002118308A (en) 2000-01-11 2000-12-15 Methods for producing polymorphic modifications of clarithromycin

Country Status (22)

Country Link
US (2) US6624292B2 (en)
EP (1) EP1280535B1 (en)
JP (1) JP2003519661A (en)
KR (1) KR20020071012A (en)
CN (1) CN1450903A (en)
AT (1) ATE288758T1 (en)
AU (2) AU2261901A (en)
BR (1) BR0016992A (en)
CA (1) CA2397092A1 (en)
DE (1) DE60018119T2 (en)
DK (1) DK1280535T3 (en)
ES (1) ES2236023T3 (en)
HR (1) HRP20020572A2 (en)
HU (1) HUP0204252A3 (en)
IL (1) IL150698A0 (en)
IS (1) IS6463A (en)
PL (1) PL356645A1 (en)
PT (1) PT1280535E (en)
RU (1) RU2002118308A (en)
SI (1) SI1280535T1 (en)
WO (1) WO2001051059A1 (en)
ZA (1) ZA200205229B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8322002A3 (en) * 1999-12-16 2003-02-04 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph IV
RU2002118308A (en) * 2000-01-11 2004-02-20 Тева Фамэситикл Индастрис Лтд. (Il) Methods for producing polymorphic modifications of clarithromycin
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CA2403757A1 (en) * 2000-03-28 2001-10-04 Biochemie Gesellschaft M.B.H. Granulated particles with masked taste
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
SI1285659T1 (en) * 2001-08-13 2008-02-29 Fond Salvatore Maugeri Clinica Use of clarithromycin compositions in the manufacture of a medicament for the treatment of arthritis deformans
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528190A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
CA2533358C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
JP2007502294A (en) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc Functionalized colloidal metal compositions and methods
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP2008505124A (en) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション Pulse delivery tablets
EP1904041A2 (en) * 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
WO2007064595A2 (en) * 2005-11-29 2007-06-07 Bausch & Lomb Incorporated Fluocinolone acetonide drug substance polymorphic interconversion
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20120219625A1 (en) * 2009-09-02 2012-08-30 Bernard Charles Sherman Clarithromycin extended-release tablet
KR102381295B1 (en) 2013-11-15 2022-03-31 아케비아 테라퓨틱스 인코포레이티드 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (en) 1980-01-11 1981-07-17 Roussel Uclaf NOVEL OXIMES DERIVED FROM ERYTHROMYCIN, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (en) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd Production method of 6-0-methylerythromycins
JPS61103890A (en) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6-0-methylerythromycin A derivative
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (en) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 Erythromycin A derivatives and preparation method thereof
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (en) 1988-05-19 1998-05-18 大正製薬株式会社 Process for producing erythromycin A oxime and its salt
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (en) * 1998-09-09 2003-08-19 한미약품공업 주식회사 Method for preparing Form 2 of clarithromycin without residual solvent
SK8322002A3 (en) * 1999-12-16 2003-02-04 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph IV
RU2002118308A (en) * 2000-01-11 2004-02-20 Тева Фамэситикл Индастрис Лтд. (Il) Methods for producing polymorphic modifications of clarithromycin
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
US6987175B2 (en) 2006-01-17
US6624292B2 (en) 2003-09-23
EP1280535A4 (en) 2003-02-05
EP1280535B1 (en) 2005-02-09
DE60018119T2 (en) 2006-05-04
HRP20020572A2 (en) 2005-04-30
CA2397092A1 (en) 2001-07-19
US20030216555A1 (en) 2003-11-20
ES2236023T3 (en) 2005-07-16
IL150698A0 (en) 2003-02-12
DK1280535T3 (en) 2005-04-04
ATE288758T1 (en) 2005-02-15
AU2001222619B2 (en) 2005-04-28
HUP0204252A3 (en) 2003-04-28
WO2001051059A1 (en) 2001-07-19
SI1280535T1 (en) 2005-08-31
BR0016992A (en) 2002-12-31
AU2261901A (en) 2001-07-24
PL356645A1 (en) 2004-06-28
HUP0204252A2 (en) 2003-03-28
CN1450903A (en) 2003-10-22
AU2001222619C1 (en) 2006-01-12
US20020028920A1 (en) 2002-03-07
AU2001222619B8 (en) 2005-07-14
JP2003519661A (en) 2003-06-24
PT1280535E (en) 2005-04-29
DE60018119D1 (en) 2005-03-17
EP1280535A1 (en) 2003-02-05
KR20020071012A (en) 2002-09-11
IS6463A (en) 2002-07-09
ZA200205229B (en) 2003-06-30

Similar Documents

Publication Publication Date Title
RU2002118308A (en) Methods for producing polymorphic modifications of clarithromycin
BG101900A (en) Crystalline forms of 2-methyl-thieno-benzodiazepine and method for their preparation
CA2121435A1 (en) Aqueous pharmaceutical suspension and process for preparation thereof
IL150227A0 (en) Processes for preparing clarithromycin polymorphs and novel polymorph iv
RU2001118035A (en) ETHANOLATE OF AZITROMYCINE, THE PROCESS OF OBTAINING AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
RU94002474A (en) Pharmaceutical composition containing nanocapsules and method of its preparing
HUT61289A (en) Process for producing pyrimidine derivatives of sulfonamides and pharmaceutical compositions comprising same
AR030056A1 (en) PROCESS FOR THE PREPARATION OF PURIFIED CITALOPRAM
EA200100955A1 (en) 4-OXO-4,7-DIHYDROTIENO [2,3-b] PYRIDIN-5-CARBOXAMIDE AS ANTI-VIRUS MEANS
RU2002105504A (en) SOLID DISPERSING AGENT OF NON-CRYSTAL CEFUROXYM-AXETHYL, METHOD FOR ITS PREPARATION AND COMPOSITION FOR ITS Oral Administration
NO20006039L (en) Process for Preparation of 4-Carboxyamino-2-Substituted-1,2,3,4-Tetrahydroquinoline
EP1676839A3 (en) Novel beta crystalline form of perindopril tert-butylamine salt, its preparation method and pharmaceutical compositions containing same
HUP9900958A1 (en) New derivatives of 2-fluoro-3-de[(2,6-dideoxy-3-c-methyl-3-0-methyl-alfa-l-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erytromycin, and their preparation process
EP1797875A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
CA2286511A1 (en) Novel macrolide derivatives
KR930016436A (en) 4,13-dioxabicyclo [8.2.1] tridesenone derivatives and preparation methods thereof, pharmaceutical compositions containing intermediates and compounds for their preparation
CA2510949A1 (en) Polymorph of ritonavir
EP0326386A3 (en) Isoquinolinones
US5912235A (en) 10, 13, 15-trioxatricyclo 9.2.1.1.9.6 !-pentadecan one derivatives, method for their production and pharmaceutical compositions containing them
MA27815A1 (en) ALPHA CRYSTALLINE FORM OF STRONTIUM RANELATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GR870824B (en) Process for the preparation of new 1,4 - dihydropyridines useful as antithrombotic drugs
NZ509561A (en) Crystalline forms of osanetant
HRP20020344B1 (en) METHOD OF PREPARATION OF CITALOPRAM
FR2794747B1 (en) NOVEL ECHINOCANDIN DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS ANTI-FUNGI
RU99100107A (en) DERIVATIVES OF DIBENZOOXAZEPINE AND DIBENZODIOXEPINE AND THEIR APPLICATION AS ANTI-TUMOR AGENTS